NCT01000922 - A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

Diabetes Mellitus

Interventions

DRUG

Regular Human Insulin

Individual dose of RHI administered subcutaneously

DRUG

Lispro

Individual dose of lispro administered subcutaneously

DRUG

VIAject

Individual dose of VIAject administered subcutaneously

DRUG

VIAject 50%

Individual dose of VIAject 50% administered subcutaneously

DRUG

VIAject/Insulin Glargine

VIAject mixed wiht insulin glargine and administered subcutaneously

DRUG

Insulin Glargine/VIAject

Individual dose of VIAject and Insulin Glargine administered seperately and subcutaneously

Trial Locations (1)

Profil Institute for Clinical Research, Inc. (PICR), Chula Vista